+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 1Year - 30Years
All Genders
ID06177067

Evaluating Revumenib Combined with Azacitidine and Venetoclax for Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

Led by St. Jude Children's Research Hospital · Updated on 2026-10-22

24

Participants Needed

10

Research Sites

108 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and possible benefits of adding a new drug called revumenib to common chemotherapy treatments in children and young adults aged 1 to 30 years who have acute myeloid leukemia AML or acute leukemia of ambiguous lineage ALAL that has not responded to previous treatments or has returned after remission. This phase 1 study aims to find the safe total dose for combining revumenib, azacitidine, and venetoclax when patients also take an anti-fungal medication. Participants will receive revumenib, azacitidine, and venetoclax in a dose-escalation manner, starting at a low dose and increasing if no severe side effects are seen. The dose of revumenib may increase or venetoclax exposure may decrease depending on tolerance, while azacitidine stays constant. Intrathecal chemotherapy with cytarabine and methotrexate is also given. Patients who benefit from revumenib alone may continue it, and those undergoing hematopoietic cell transplant will stop therapy at transplant but remain in the study. During the study, participants will be monitored for safety and tolerability over about 43 days from the start of therapy. Researchers will also assess remission rates and overall survival up to one year. Treatment involves oral medications, intravenous infusions, and spinal injections. Participants will have regular evaluations including lab tests and clinical assessments to track response and side effects throughout the study period.

CONDITIONS

Brief Title

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Research Team

H

Hiroto Inaba, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here